Last Modified: November 1, 2001
Last Updated: 2001-02-20 17:30:38 EST (Reuters Health) - Antibodies against prostate stem-cell antigen (PSCA), a cell-surface antigen overexpressed in prostate cancer tissues, may have therapeutic potential in the treatment of prostate cancer, according to the results of an animal study published online in the February 13th Early Edition of the Proceedings of the National Academy of Sciences.
Dr. Aya Jakobovits, from UroGenesys, Inc. in Santa Monica, California, and colleagues assessed the therapeutic efficacy of two different anti-PSCA antibodies in mice bearing human prostate cancer xenografts.
Both antibodies inhibited subcutaneous and orthotopic xenograft tumors in a dose-dependent fashion, the authors state. In addition, with anti-PSCA therapy, established tumor growth was retarded and distant metastatic disease was inhibited, resulting in significantly prolonged survival.
"Our studies demonstrate a broad antitumor efficacy of anti-PSCA antibodies on initiation and progression of prostate cancer in xenograft mouse models," the researchers conclude. "PSCA is one of the few largely prostate-specific cell-surface antigens that represent potential antibody therapy targets for prostate cancer."
Online Proc Natl Acad Sci USA 2001. February 13, 2001;doc 6246.
Sep 5, 2013 - For patients with glioblastoma, treatment with the anti-cytomegalovirus agent valganciclovir is associated with improved survival, according to a study published in the Sept. 5 issue of the New England Journal of Medicine.
Nov 12, 2010
Oct 20, 2014